Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase II study set to open this month evaluating Zyflo for acne

Oct. 13, 2004

New androgen receptor antagonists in early development at Pfizer

Oct. 13, 2004

rHuEPO active in wound healing

Oct. 11, 2004

Novel melanogenesis inhibitors developed at Takasago

Oct. 8, 2004

Germany marks first European launch of Raptiva

Oct. 7, 2004

OraDisc A approved for aphthous ulcers

Oct. 7, 2004

Enbrel approved in E.U. for psoriasis

Oct. 5, 2004

Pierre Fabre to commercialize Olux in Europe

Oct. 5, 2004

Approval sought for proof-of-concept study for ATL-1101 in psoriasis

Oct. 4, 2004

European approval for Raptiva for psoriasis

Sep. 30, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.